Delta Investment Management LLC Makes New $146,000 Investment in OptimizeRx Co. (NASDAQ:OPRX)

Delta Investment Management LLC acquired a new position in shares of OptimizeRx Co. (NASDAQ:OPRX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 30,000 shares of the company’s stock, valued at approximately $146,000. Delta Investment Management LLC owned 0.16% of OptimizeRx at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of OPRX. SBI Securities Co. Ltd. acquired a new stake in OptimizeRx during the 4th quarter worth about $25,000. SG Americas Securities LLC acquired a new position in shares of OptimizeRx in the 4th quarter valued at about $51,000. Wells Fargo & Company MN increased its holdings in shares of OptimizeRx by 33.3% in the 4th quarter. Wells Fargo & Company MN now owns 11,208 shares of the company’s stock valued at $54,000 after purchasing an additional 2,797 shares during the period. Graham Capital Management L.P. acquired a new position in shares of OptimizeRx in the 4th quarter valued at about $81,000. Finally, BNP Paribas Financial Markets increased its holdings in shares of OptimizeRx by 504.6% in the 4th quarter. BNP Paribas Financial Markets now owns 22,308 shares of the company’s stock valued at $108,000 after purchasing an additional 18,618 shares during the period. Institutional investors and hedge funds own 76.47% of the company’s stock.

Insiders Place Their Bets

In related news, Director James Paul Lang bought 321,408 shares of the firm’s stock in a transaction on Friday, March 14th. The stock was purchased at an average price of $7.60 per share, with a total value of $2,442,700.80. Following the completion of the transaction, the director now directly owns 389,452 shares of the company’s stock, valued at $2,959,835.20. This trade represents a 472.35% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 5.60% of the company’s stock.

OptimizeRx Trading Down 2.0%

NASDAQ:OPRX opened at $11.95 on Wednesday. The stock’s 50 day moving average price is $8.95 and its 200 day moving average price is $6.57. OptimizeRx Co. has a 52 week low of $3.78 and a 52 week high of $13.19. The company has a market capitalization of $221.02 million, a P/E ratio of -8.98 and a beta of 1.28. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23.

OptimizeRx (NASDAQ:OPRX) last released its quarterly earnings data on Monday, May 12th. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.19. OptimizeRx had a negative return on equity of 4.92% and a negative net margin of 27.41%. The firm had revenue of $21.93 million for the quarter, compared to the consensus estimate of $18.69 million. On average, research analysts forecast that OptimizeRx Co. will post -0.33 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on OPRX shares. Stifel Nicolaus upped their target price on OptimizeRx from $8.00 to $12.50 and gave the company a “buy” rating in a report on Tuesday, May 13th. B. Riley reiterated a “buy” rating on shares of OptimizeRx in a report on Tuesday, May 13th. Roth Capital reiterated a “buy” rating on shares of OptimizeRx in a report on Tuesday, May 13th. Citigroup reiterated an “outperform” rating on shares of OptimizeRx in a report on Tuesday, May 13th. Finally, JMP Securities upped their target price on OptimizeRx from $11.00 to $14.00 and gave the company a “market outperform” rating in a report on Tuesday, May 13th. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $10.38.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.